WO2025006723A3 - Agonistes de tmem175, compositions et procédés d'utilisation - Google Patents

Agonistes de tmem175, compositions et procédés d'utilisation Download PDF

Info

Publication number
WO2025006723A3
WO2025006723A3 PCT/US2024/035781 US2024035781W WO2025006723A3 WO 2025006723 A3 WO2025006723 A3 WO 2025006723A3 US 2024035781 W US2024035781 W US 2024035781W WO 2025006723 A3 WO2025006723 A3 WO 2025006723A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
tmem175
agonists
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/035781
Other languages
English (en)
Other versions
WO2025006723A2 (fr
Inventor
Rajesh R. Iyengar
Thomas Wai-Ho Lee
Darby R. Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caraway Therapeutics Inc
Original Assignee
Caraway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caraway Therapeutics Inc filed Critical Caraway Therapeutics Inc
Priority to EP24832917.9A priority Critical patent/EP4734979A2/fr
Publication of WO2025006723A2 publication Critical patent/WO2025006723A2/fr
Publication of WO2025006723A3 publication Critical patent/WO2025006723A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente divulgation concerne des composés de formule I ou un sel pharmaceutiquement acceptable de ceux-ci, les variables étant telles que définies dans la description. L'invention concerne également des compositions comprenant lesdits composés et des méthodes d'utilisation pour traiter certaines maladies ou certains troubles, y compris, par exemple, des maladies neurodégénératives et des maladies lysosomales.
PCT/US2024/035781 2023-06-29 2024-06-27 Agonistes de tmem175, compositions et procédés d'utilisation Ceased WO2025006723A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24832917.9A EP4734979A2 (fr) 2023-06-29 2024-06-27 Agonistes de tmem175, compositions et procédés d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363524085P 2023-06-29 2023-06-29
US202363524082P 2023-06-29 2023-06-29
US63/524,082 2023-06-29
US63/524,085 2023-06-29

Publications (2)

Publication Number Publication Date
WO2025006723A2 WO2025006723A2 (fr) 2025-01-02
WO2025006723A3 true WO2025006723A3 (fr) 2025-05-01

Family

ID=93940221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/035781 Ceased WO2025006723A2 (fr) 2023-06-29 2024-06-27 Agonistes de tmem175, compositions et procédés d'utilisation

Country Status (2)

Country Link
EP (1) EP4734979A2 (fr)
WO (1) WO2025006723A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621097A (en) * 1985-08-16 1986-11-04 Warner-Lambert Company Saturated cycloalkyl[c] pyrrole-2(1H)-acetic acid amides and derivatives thereof
US20210379052A1 (en) * 2018-09-27 2021-12-09 Shenzhen Chipscreen Biosciences Co., Ltd. Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity
WO2023021278A1 (fr) * 2021-08-16 2023-02-23 Redx Pharma Plc Dérivés de phényle et de pyridopyrazole en tant qu'inhibiteurs de ddr1
WO2024108155A2 (fr) * 2022-11-17 2024-05-23 Denali Therapeutics Inc. Composés, compositions et méthodes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621097A (en) * 1985-08-16 1986-11-04 Warner-Lambert Company Saturated cycloalkyl[c] pyrrole-2(1H)-acetic acid amides and derivatives thereof
US20210379052A1 (en) * 2018-09-27 2021-12-09 Shenzhen Chipscreen Biosciences Co., Ltd. Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity
WO2023021278A1 (fr) * 2021-08-16 2023-02-23 Redx Pharma Plc Dérivés de phényle et de pyridopyrazole en tant qu'inhibiteurs de ddr1
WO2024108155A2 (fr) * 2022-11-17 2024-05-23 Denali Therapeutics Inc. Composés, compositions et méthodes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND 31 July 2006 (2006-07-31), XP093312104, Database accession no. 9354358 *

Also Published As

Publication number Publication date
EP4734979A2 (fr) 2026-05-06
WO2025006723A2 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
WO2024075070A3 (fr) Nouveaux composés hétérocyclyle bicycliques et leur utilisation
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
MX2024000299A (es) Compuestos antivirales.
MX2023012187A (es) Derivados de fosforo como nuevos inhibidores de sos1.
WO2024189598A3 (fr) Inhibiteurs de kat6a de type acylsulfonamides
WO2024006726A3 (fr) Composés utilisés en tant qu'inhibiteurs d'axl
PH12021552513A1 (en) Pyrrole compounds
WO2023122783A3 (fr) Tétrahydropyrazolopyrimidines et analogues associés pour inhiber yap/taz-tead
WO2003097025A3 (fr) Procede de preparation de compositions pharmaceutiques contenant des composes 4-aminoquinolines pour le traitement de troubles inflammatoires de l'oeil, compositions resultantes et methode de traitement de ces troubles au moyen de ces compositions
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
GEAP202516737A (en) Compounds for treating cancer
WO2020096916A3 (fr) Inhibiteurs de désacétylase d'histone utiles pour traiter ou prévenir une infection par le vih
WO2025006726A3 (fr) Agonistes de tmem175, compositions et procédés d'utilisation
WO2006026204A3 (fr) Nouvelles gamma-lactames servant d'inhibiteurs de beta-secretase
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
WO2023023534A3 (fr) Composés d'arylsulfonyle en tant qu'inhibiteurs de ccr6
WO2024238763A3 (fr) Tétrahydronaphtyridine et analogues associés pour l'inhibition de yap/taz-tead
WO2024215870A3 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de polymérase thêta et leurs procédés d'utilisation
WO2024239001A3 (fr) Analogues d'isoandrographolide et méthode de traitement les utilisant
WO2024249254A3 (fr) Procédés d'utilisation d'inhibiteurs d'apol1
WO2020251871A3 (fr) Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
WO2024124023A3 (fr) Inhibiteurs d'enzyme anhydrase carbonique et leurs procédés d'utilisation
WO2023141522A3 (fr) Composés multicycliques
WO2024145288A3 (fr) Méthodes d'administration de r-kétamine
WO2006065721A3 (fr) Bicyclolides de 11, 12-lactone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024832917

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024832917

Country of ref document: EP

Effective date: 20260129

ENP Entry into the national phase

Ref document number: 2024832917

Country of ref document: EP

Effective date: 20260129

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24832917

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2024832917

Country of ref document: EP